|
|||||
|
|
Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy |
|
| Authors: | M. Guzm��n-Fulgencio J. Berenguer M. Garc��a-��lvarez D. Micheloud J. C. L��pez J. Cos��n I. Fern��ndez de Castro P. Catal��n P. Miralles S. Resino |
| Affiliation: | 1. Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain 2. Infectious Diseases??HIV Unit, Hospital General Universitario ??Gregorio Mara???n??, Madrid, Spain 3. Internal Medicine Department, Hospital General Universitario ??Gregorio Mara???n??, Madrid, Spain 4. Microbiology Department, Hospital General Universitario ??Gregorio Mara???n??, Madrid, Spain 5. Centro Nacional de Microbiolog??a, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda-Pozuelo, Km 2.2, Majadahonda, Madrid, 28220, Spain |
| Abstract: | The aim of this study was to evaluate the influence of clinical and epidemiological characteristics of 183 HIV/HCV coinfected patients and HCV clearance after antiviral treatment on serum sFas and sFasL levels. Thirty out of 183 patients underwent HCV antiviral therapy with IFN-???+?RBV for a duration of 48?weeks. HCV genotype 1 and homeostasis model assessment for insulin resistance (HOMA-IR) had a significant positive relationship, and CD4+/??L had a significant negative relationship with sFas (R-square?=?0.582; p?R-square?=?0.216; p?R-square?=?0.201; p?p?p?=?0.008) and sFas/sFasL ratio (p?=?0.002), while non-responders had a significant increase in sFasL values (p?=?0.013). In conclusion, HCV genotype 1, high HOMA, and low CD4+/??L were associated with high serum levels of sFas and sFasL, which indicate higher levels of inflammation and, possibly, increased cardiovascular risk. Moreover, response to HCV antiviral therapy is known to reduce inflammation. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |